Clene Inc. Stock News

Equities analysts expect that Clene Inc. (NASDAQ:CLNN) will post earnings per share (EPS) of ($0.18) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Clenes earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.17). The company is scheduled to issue [] The post Zacks: Brokerages Anticipate Clene Inc. (NASDAQ:CLNN) Will Announce Earnings of -$0.18 Per Share appeared first on ETF Daily News .

Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% to close at $4.70. East Stone Acquisition Corporation (NASDAQ: ESSC ) jumped 31.4% to close at $18.40 after gaining over 8% on Friday. Puxin Limited (NYSE: NEW ) climbed 27.1% to settle at $0.41 after tumbling over 10% on Friday.

The stock price of Clene Inc. (NASDAQ: CLNN) increased by 13.12% in the most recent trading session. This is why it happened.

Clene Inc. (NASDAQ:CLNN) Director David J. Matlin bought 15,000 shares of the stock in a transaction on Friday, December 10th. The shares were acquired at an average price of $4.87 per share, with a total value of $73,050.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. []

Clene Inc. (NASDAQ:CLNN) Director David J. Matlin purchased 15,000 shares of Clene stock in a transaction on Friday, December 10th. The stock was purchased at an average price of $4.87 per share, for a total transaction of $73,050.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible []

SALT LAKE CITY, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biophar

SALT LAKE CITY, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma

SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced the 32nd International Symposium on ALS/MND , a Motor Neurone Disease (MND) Association event, has selected Clenes Phase 2 RESCUE-ALS clinical trial results of CNM-Au8 ® , a gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) for a late-breaking oral presentation as well as a poster presentation.

Clene Inc. (CLNN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 287.8% upside potential for Clene Inc. (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim

The consensus price target hints at a 287.8% upside potential for Clene Inc. (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim

Clene Inc (NASDAQ: CLNN ) presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension for amyotrophic lateral sclerosis (ALS). Data were shared at the 4th Annual ALS ONE Research Symposium. New data presented included analyses of CNM-Au8''s efficacy in limb and bulbar onset participants across critical endpoints of slowing ALS Full story available on Benzinga.com

CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change a clinically meaningful endpoint recommended by the FDA CNM-Au8 showed consistent efficacy across limb and bulbar onset participants for ALS disease progression and the proportion with less than a 6-point decline on the ALSFRS-R scale SALT LAKE CITY, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN ) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8 ® , a catalytically active gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) at the 4th Annual ALS ONE Research Symposium which took place virtually on November 30, 2021. The presentation can be viewed on Clene''s website at: https://invest.clene.com/overview/default.aspx New data presented included analyses of CNM-Au8''s efficacy in limb and bulbar onset participants across key endpoints of slowing ALS clinical worsening: Consistent clinical benefit was shown in both limb and bulbar onset participants for the pre-specified endpoint of ALS disease progression defined as death, or the need for tracheostomy, non-invasive ventilation, or gastrostomy.

Nuveen Asset Management LLC acquired a new position in shares of Clene Inc. (NASDAQ:CLNN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 54,870 shares of the companys stock, valued at approximately $617,000. Nuveen Asset Management LLC owned approximately 0.09% of Clene [] The post 54,870 Shares in Clene Inc. (NASDAQ:CLNN) Acquired by Nuveen Asset Management LLC appeared first on ETF Daily News .